Surgically Resected Second Primary Lung Adenocarcinoma After Pembrolizumab Administration
Surgically Resected Second Primary Lung Adenocarcinoma After Pembrolizumab Administration
复制标题
给予派姆单抗后手术切除第二原发性肺腺癌
DOI：
10.1016/j.athoracsur.2020.03.059
复制
发表时间：
2020
期刊：
影响因子：
--
通讯作者：
Takenoyama Mitsuhiro
中科院分区：
文献类型：
--
作者：
Takamori Shinkichi;Matsubara Taichi;Haratake Naoki;Miura Naoko;Yamaguchi Masafumi;Toyozawa Ryo;Seto Takashi;Taguchi Kenichi;Takenoyama Mitsuhiro
非小细胞肺癌（NSCLC）患者有时会被转诊进行胸外科会诊，以解决切除第二原发性肺癌的可能性。我们报告了一例在原发性转移性肺腺癌得到控制的情况下，在接受3个周期的帕博利珠单抗治疗后进行第二原发性肺腺癌肺切除术的病例。肿瘤状态，包括程序性死亡配体1，表皮生长因子受体，和CD8+肿瘤浸润淋巴细胞，手术切除标本和以前的活检样本之间是不同的。如果原发性NSCLC在免疫检查点抑制剂治疗后得到良好控制，则应考虑对第二原发性NSCLC进行手术治疗。
Non-small cell lung cancer (NSCLC) patients are sometimes referred for thoracic surgical consultation to address the possibility of resecting second primary lung cancer. We report a case of pulmonary resection for second primary lung adenocarcinoma after 3 cycles of pembrolizumab under circumstances in which the primary metastatic lung adenocarcinoma was controlled. The tumor statuses, including programmed death-ligand 1, epidermal growth factor receptor, and CD8+ tumor-infiltrating lymphocytes, were different between the surgically resected specimen and the previously biopsied sample. Surgery should be considered for second primary NSCLC in cases in which the primary NSCLC are well controlled with immune checkpoint inhibitors.